Kidney

Carcinoma

Biology

Paclitaxel

Urology

Cancer research

Biochemistry

Urinary bladder

Renal cell carcinoma

In vitro

Gemcitabine

Internal medicine

Cytotoxic T cell

Oncology

Medicine

Chemistry

Urinary system

Cancer

Pathology

The Journal of Urology

No AccessJournal of UrologyINVESTIGATIVE UROLOGY1 Dec 1999ACTIVITY OF STANDARD AND INVESTIGATIONAL CYTOTOXIC DRUGS IN PRIMARY CULTURES OF TUMOR CELLS FROM PATIENTS WITH KIDNEY AND URINARY BLADDER CARCINOMAS PETER NYGREN, KATALIN CSÒKA, ROLF LARSSON, CHRISTER BUSCH, KENNETH WESTER, and PER-UNO MALMSTRÖM PETER NYGRENPETER NYGREN More articles by this author , KATALIN CSÒKAKATALIN CSÒKA More articles by this author , ROLF LARSSONROLF LARSSON More articles by this author , CHRISTER BUSCHCHRISTER BUSCH More articles by this author , KENNETH WESTERKENNETH WESTER More articles by this author , and PER-UNO MALMSTRÖMPER-UNO MALMSTRÖM More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)68159-1AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: In vitro tumor models could support the process of development of new cytotoxic drugs and selection of suitable drugs for the individual patient. We investigated whether the testing of tumor cells from patients with kidney or urinary bladder carcinoma by fluorometric microculture cytotoxicity assay (FMCA) could provide clinically relevant data for these tumor types. Materials and Methods: A total of 45 tumor samples from patients with kidney or urinary bladder carcinoma were compared with 247 samples of other tumor types with respect to sensitivity to 8 standard and 6 investigational cytotoxic drugs in the FMCA, a 72 hour assay based on the concept of total cell kill. In bladder carcinomas, sensitivity to standard drugs was correlated to various tumor characteristics. Results: The technical success rate for kidney and bladder carcinomas was high; approximately 90% of the samples could be analyzed successfully. Kidney carcinomas were highly resistant to standard drugs and bladder carcinomas essentially as sensitive as carcinomas of the breast and ovary but with a steeper dose-response relationship. In bladder carcinoma there was no clear relationship between tumor stage, grade, ploidy, mitoses or p53 expression and drug sensitivity. Except for suramin, kidney carcinomas were poorly sensitive to the investigational drugs CdA, gemcitabine, paclitaxel, vinorelbine and topotecan. In bladder carcinomas paclitaxel, gemcitabine and suramin showed promising activity. Conclusions: The FMCA seems suitable for cytotoxic drug sensitivity testing of urinary tract carcinomas. This technique may have a role in new drug development in these tumor types. References 1 : Cancer of the bladder. In: . Philadelphia: Lippincott-Raven Publishers1997: 1300. Google Scholar 2 : Cancer of the kidney and ureter. In: . Philadelphia: Lippincott-Raven Publishers1997: 1271. Google Scholar 3 : In vitro determination of drug response: a discussion of clinical applications. PPO Updates1993; 7: 1. Google Scholar 4 : Detection of tumor specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int. J. Cancer1994; 56: 715. Crossref, Medline, Google Scholar 5 : A feasibility study of the fluorometric microculture cytotoxicity assay (FMCA) in ovarian malignancy. Gynecol. Oncol.1993; 54: 163. Crossref, Google Scholar 6 : Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs. Anti-Cancer Drugs1995; 6: 64. Crossref, Medline, Google Scholar 7 Fridborg H. Feasibility of the flurometric microculture cytotoxicity assay (FMCA) in the preclinical evaluation of anticancer drugs. Thesis, Uppsala University, Uppsala, 1996. Google Scholar 8 : Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer1992; 50: 177. Crossref, Medline, Google Scholar 9 : Recurrence, progression and survival in bladder cancer. A retrospective study of 232 patients with more than 5 years follow-up. Scand. J. Urol. Nephrol.1987; 21: 185. Crossref, Medline, Google Scholar 10 : A grading system for the immunostaining of A, B and H blood group isoantigens in bladder carcinoma. Anticancer Res.1987; 8: 31. Google Scholar 11 : Flow cytometric analysis of DNA content of deparaffinized nuclei in urinary bladder carcinomas. Acta Pathol. Microbiol. Scand.1993; 97: 811. Google Scholar 12 : Prognstic value of a systematized method for determination of mitotic frequency in bladder cancer assisted by image analysis. J. Urogenital Pathol.1991; 1: 53. Google Scholar 13 : Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia1992; 6: 1121. Medline, Google Scholar 14 : In vitro analysis in of drug resistance in tumor cells from patients with acute myelocytic leukemia. Med. Oncol. Tumor Pharmacother.1992; 9: 65. Crossref, Medline, Google Scholar 15 : In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin’s lymphoma using the fluorometric microculture cytotoxicity assay (FMCA). Ann. Oncol.1994; 5: 127. Crossref, Medline, Google Scholar 16 : In vitro determination of cytotoxic drug-response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer1997; 17: 1008. Crossref, Google Scholar 17 : Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N. Engl. J. Med.1993; 328: 614. Crossref, Medline, Google Scholar 18 : Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst.1996; 88: 1442. Crossref, Medline, Google Scholar 19 : Phase II study of etoposide in genitourinary tumors. Gan To Kagaku Ryoho1986; 13: 2772. Medline, Google Scholar 20 : High-dose intensity systemic therapy of metastatic bladder cancer. J. Clin. Oncol.1987; 5: 450. Crossref, Medline, Google Scholar 21 : Evaluation for systemic chemotherapy with methotrexate, vinblastine, adriamycin and cisplatin for advanced bladder cancer. Cancer Chemother. Pharmacol.1992; 30: S85. Crossref, Medline, Google Scholar 22 : Single-agent activity of gemcitabine in advanced non-small cell lung cancer. Semin. Oncol.1996; 23: 36. Medline, Google Scholar 23 : Phase II activity of gemcitabine in advanced breast cancer. Semin. Oncol.1996; 23: 77. Medline, Google Scholar 24 : Gemcitabine in cisplatin-resistant ovarian cancer. Semin. Oncol.1996; 23: 72. Medline, Google Scholar 25 : Metastatic bladder cancer: advances in treatment. Eur. J. Cancer1997; 33: S23. Crossref, Medline, Google Scholar 26 : Suramin: defining the role in the clinic. PPO Updates1993; 7: 1. Google Scholar 27 : Intravesical suramin: a novel agent for the treatment of superficial transitional carcinoma of the bladder. World J. Urol.1996; 14: S8. Crossref, Medline, Google Scholar 28 : Paclitaxel (Taxol). N. Engl. J. Med.1995; 332: 1004. Crossref, Medline, Google Scholar 29 : Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest.1991; 9: 133. Crossref, Medline, Google Scholar 30 : Preliminary experience with paclitaxel in advanced bladder cancer. Semin. Oncol.1995; 22: 1. Medline, Google Scholar From the Departments of Oncology, Clinical Pharmacology, Pathology and Urology, University Hospital, Uppsala, Sweden and the Department of Medical Biology, University of Tromsö, Tromsö, Norway© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Gårdmark T, Carringer M, Beckman E and Malmström P (2005) Randomized Phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladderUrology, 10.1016/j.urology.2005.03.084, VOL. 66, NO. 3, (527-530), Online publication date: 1-Sep-2005. Malmström P (2003) Intravesical therapy of superficial bladder cancerCritical Reviews in Oncology/Hematology, 10.1016/S1040-8428(03)00075-1, VOL. 47, NO. 2, (109-126), Online publication date: 1-Aug-2003. KIELB S, SHAH N, RUBIN M and SANDA M (2018) FUNCTIONAL p53 MUTATION AS A MOLECULAR DETERMINANT OF PACLITAXEL AND GEMCITABINE SUSCEPTIBILITY IN HUMAN BLADDER CANCERJournal of Urology, VOL. 166, NO. 2, (482-487), Online publication date: 1-Aug-2001. Malmström P (2000) Management of superficial bladder cancer: what is new?Current Opinion in Urology, 10.1097/00042307-200009000-00014, VOL. 10, NO. 5, (447-451), Online publication date: 1-Sep-2000. Volume 162Issue 6December 1999Page: 2200-2204 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.Keywordskidney cancerin vitrourinary bladder cancercytotoxic drugMetricsAuthor Information PETER NYGREN More articles by this author KATALIN CSÒKA More articles by this author ROLF LARSSON More articles by this author CHRISTER BUSCH More articles by this author KENNETH WESTER More articles by this author PER-UNO MALMSTRÖM More articles by this author Expand All Advertisement PDF downloadLoading ...

ACTIVITY OF STANDARD AND INVESTIGATIONAL CYTOTOXIC DRUGS IN PRIMARY CULTURES OF TUMOR CELLS FROM PATIENTS WITH KIDNEY AND URINARY BLADDER CARCINOMAS